Your browser doesn't support javascript.
loading
Statistical approaches applicable in managing OMICS data: Urinary proteomics as exemplary case.
An, De-Wei; Yu, Yu-Ling; Martens, Dries S; Latosinska, Agnieszka; Zhang, Zhen-Yu; Mischak, Harald; Nawrot, Tim S; Staessen, Jan A.
Afiliação
  • An DW; Non-Profit Research Association Alliance for the Promotion of Preventive Medicine, Mechelen, Belgium.
  • Yu YL; Research Unit Environment and Health, KU Leuven Department of Public Health and Primary Care, University of Leuven, Leuven, Belgium.
  • Martens DS; Non-Profit Research Association Alliance for the Promotion of Preventive Medicine, Mechelen, Belgium.
  • Latosinska A; Research Unit Environment and Health, KU Leuven Department of Public Health and Primary Care, University of Leuven, Leuven, Belgium.
  • Zhang ZY; Centre for Environmental Sciences, Hasselt University, Hasselt, Belgium.
  • Mischak H; Mosaiques Diagnostics GmbH, Hannover, Germany.
  • Nawrot TS; Research Unit Hypertension and Cardiovascular Epidemiology, KU Leuven Department of Cardiovascular Sciences, University of Leuven, Leuven, Belgium.
  • Staessen JA; Mosaiques Diagnostics GmbH, Hannover, Germany.
Mass Spectrom Rev ; 2023 May 04.
Article em En | MEDLINE | ID: mdl-37143314
ABSTRACT
With urinary proteomics profiling (UPP) as exemplary omics technology, this review describes a workflow for the analysis of omics data in large study populations. The proposed workflow includes (i) planning omics studies and sample size considerations; (ii) preparing the data for analysis; (iii) preprocessing the UPP data; (iv) the basic statistical steps required for data curation; (v) the selection of covariables; (vi) relating continuously distributed or categorical outcomes to a series of single markers (e.g., sequenced urinary peptide fragments identifying the parental proteins); (vii) showing the added diagnostic or prognostic value of the UPP markers over and beyond classical risk factors, and (viii) pathway analysis to identify targets for personalized intervention in disease prevention or treatment. Additionally, two short sections respectively address multiomics studies and machine learning. In conclusion, the analysis of adverse health outcomes in relation to omics biomarkers rests on the same statistical principle as any other data collected in large population or patient cohorts. The large number of biomarkers, which have to be considered simultaneously requires planning ahead how the study database will be structured and curated, imported in statistical software packages, analysis results will be triaged for clinical relevance, and presented.
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Prognostic_studies / Risk_factors_studies Idioma: En Ano de publicação: 2023 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Prognostic_studies / Risk_factors_studies Idioma: En Ano de publicação: 2023 Tipo de documento: Article